Novartis Discontinues Sabatolimab Development After Unsuccessful Study

Novartis has discontinued the development of its blood cancer prospect, Sabatolimab, following the unsuccessful outcome of a research study that did not achieve its key objective.  

The corporation revealed in its Q4 report that it is discontinuing the Sabatolimab project following the inability to allocate time to other crucial projects within its portfolio.  

The late-stage study examined the candidate with azacitidine in first-line treatment for patients with high-risk MDS or CMML-2 not eligible for intensive chemotherapy or HSCT.   

High-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukaemia-2 (CMML-2) are terms used in the classification of certain blood disorders.  

The research was an international, randomized, dual-arm, parallel-group, confidential, placebo-controlled study that involved just over 500 individuals.  

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.